RHUBARB AND ANGIOTENSIN CONVERTING ENZYME INHIBITOR STUDY (RACE) II

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 中国的患者建议大黄提取物单独使用时与ACEI提供的保护等同。此外，当与ACEI联合使用时，大黄的肾脏保护作用似乎是相加的。 大黄提取物是一种中草药制剂，在中国和其他亚洲国家广泛用于治疗便秘和CKD。其预防慢性肾脏病进展的作用机制尚不确定，但可能与抑制转化生长因子β和肿瘤坏死因子α有关。 本研究是一项前瞻性随机双盲安慰剂对照研究，旨在评价Risk联合ACEI预防成人糖尿病患者CKD进展的疗效。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Patients in China has suggested that rhubarb extract when used alone is equivalent to the protection afforded by ACEI. Furthermore when used in combination with ACEI, the renoprotective effect of rhubarb appears to be additive. Rhubarb extract is a chinese herbal preparation that is used extensively in china and other asian countries to treat constipation and CKD. Its mechanism of action in preventing progression of CKD is uncertain but perhaps related to TGF beta and TNF alph inhibition. The proposed study will be a prospective randomized double blinded placebo controlled study design to evaluate the efficacy of Rhubarb in addition to ACEI in proventing progression of CKD in adult patients with diabetes.